Intercept Pharmaceuticals Stock News

MORRISTOWN, N.J., Dec. 08, 2022 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics

Intercept (ICPT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Analysts have provided the following ratings for Intercept Pharmaceuticals (NASDAQ:ICPT) within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 1

First-in-human data shared at The Liver Meeting® 2022 supported a favorable safety and tolerability profile for INT-787 in healthy adults

Efficacy of OCA vs. placebo and external controls accepted as a late-breaker poster

The 16.4% sales growth of Ocaliva (obeticholic acid or OCA) over the prior year quarter helped lift shares 13.4%. Presentations next week at The Liver Meeting will give a first clinical look at INT-78

Analysts have provided the following ratings for Intercept Pharmaceuticals (NASDAQ:ICPT) within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 1

Within the last quarter, Intercept Pharmaceuticals (NASDAQ:ICPT) has observed the following analyst ratings:   Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 1 3 2

Intercept (ICPT) posts a wider loss in Q3 due to a loss on extinguishment of debt but beats on sales. Management increases annual sales guidance.

Intercept (ICPT) posts a wider loss in Q3 due to a loss on extinguishment of debt but beats on sales. Management increases annual sales guidance.

Gainers Abiomed, Inc. (NASDAQ: ABMD) shares surged 49.9% to settle at $377.82 on Tuesday after Johnson & Johnson announced it will acquire the company . Also, the company reported better-than-expec

U.S. stocks closed lower on Tuesday, with the Nasdaq Composite dropping around 100 points. Here is the list of some big stocks recording gains in the previous session. Abiomed, Inc. (NASDAQ: ABMD) s

Investors are cheering the drugmaker's Q3 update.

Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT ) Q3 2022 Earnings Conference Call November 1, 2022 8:30 AM ET Company Participants Nareg Sagherian - Executive Director, Global IR Jerome Durso - Presiden

Intercept (ICPT) delivered earnings and revenue surprises of -159.49% and 2.62%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?